Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Reporting Period: Quarterly period ended December 31, 1996 (Six months ended December 31, 1996).
Status: Development stage company engaged in R&D for synthetic plasma expanders, blood substitutes, and organ preservation solutions. No significant operating revenues generated to date.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1996 | Six Months Ended Dec 31, 1995 | Cumulative from Inception |
|---|---|---|---|
| Total Revenues | $39,965 | $79,060 | $769,297 |
| Net Loss | $(1,472,843) | $(800,802) | $(9,537,314) |
| Net Loss Per Share | $(0.53) | $(0.31) | $(4.73) |
| Cash and Equivalents (End of Period) | $1,832,976 | $2,318,780 | N/A |
| Net Cash Used in Operating Activities | $(1,134,603) | $(1,106,296) | $(9,010,947) |
| Total Assets | $2,317,772 | $2,968,474 (June 30, 1996) | N/A |
| Accounts Payable | $321,912 | $129,229 (June 30, 1996) | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased from $79,060 in the prior six-month period to $39,965. This is primarily due to a reduction in interest income caused by lower cash balances.
- Expense Increases:
- R&D Expenses: Increased to $917,825 (from $539,858) due to the initiation of Phase III human clinical trials for Hextend(R).
- G&A Expenses: Increased to $594,983 (from $340,004) driven by higher personnel costs and $50,136 in amortization of capitalized service costs related to financial advisor warrants.
- Cash Position: Cash and cash equivalents decreased by approximately $610,000 during the six-month period, reflecting net cash used in operations.
Outlook, Risks, and Management Commentary
- Clinical Trials: The company is conducting a Phase III clinical trial for Hextend(R) involving approximately 150 patients at Duke University and Mt. Sinai. The trial began in October 1996 and is proceeding as expected.
- Capital Needs: Management expects losses to continue for the foreseeable future. Additional financing is required to complete clinical trials, prepare New Drug Applications (NDA), and potentially acquire manufacturing facilities.
- Subsequent Financing: On February 4, 1997, the company completed a subscription rights offering raising $5,662,180. Additionally, $772,271 was received from warrant exercises between late December 1996 and February 1997.
- Strategic Partnerships: Negotiations are ongoing with major pharmaceutical companies for manufacturing and marketing agreements. If these fail, the company may need to build its own production and marketing infrastructure, requiring significant additional capital.
- Risks: Success depends on regulatory approvals (FDA), adequate capital maintenance, and achieving sales levels sufficient to support the cost structure.
Investor Verification Checklist
- Verify the status and preliminary results of the Phase III clinical trial for Hextend(R) at Duke University and Mt. Sinai.
- Confirm the utilization of the $5.66 million raised in the February 1997 rights offering and its impact on the runway for future operations.
- Assess the progress of negotiations with pharmaceutical partners for manufacturing and marketing rights.
- Monitor the burn rate of cash given the company's lack of significant operating revenue and continued R&D expenditures.
- Review the terms of the financial advisor warrants and their potential dilution impact on existing shareholders.